Alternatives to unfractioned heparin for anticoagulation in cardiopulmonary bypass

Perfusion

Volumn 16, Issue 5, 2001, Pages 411-416

  von Segesser, Ludwig K ^a   Mueller, X ^a   Marty, B ^a   Horisberger, J ^a   Corno, A ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANCROD; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A; CHONDROITIN SULFATE; DANAPAROID; DERMATAN SULFATE; DRUG DERIVATIVE; HEPARAN SULFATE; HEPARIN; IMMUNOGLOBULIN F(AB) FRAGMENT; LOW MOLECULAR WEIGHT HEPARIN; MONOCLONAL ANTIBODY; PIPECOLIC ACID DERIVATIVE; PROTAMINE; TIROFIBAN; TYROSINE; APTAMER; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING INHIBITOR; ECARIN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HIRUGEN; HIRULOG; LEPIRUDIN; PENTASACCHARIDE; RECOMBINANT HIRUDIN; RECOMBINANT TICK ANTICOAGULANT PEPTIDE; TISSUE FACTOR PATHWAY INHIBITOR;

ANTICOAGULANT THERAPY; BLEEDING; CARDIOPULMONARY BYPASS; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; CROSS REACTION; DRUG ANTAGONISM; DRUG COMBINATION; DRUG HYPERSENSITIVITY; HEMODILUTION; HUMAN; PERFUSION; REVIEW; THROMBOCYTOPENIA; THROMBOPHILIA; THROMBOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; BLOOD DONOR; CARDIOLOGY; DEVICE; DOG; DRUG ACTIVITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; EXTRACORPOREAL CIRCULATION; HEPARINIZATION; MEDICAL ASSESSMENT; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE TRANSFUSION;

ANCROD; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CARDIOPULMONARY BYPASS; CHONDROITIN SULFATES; CROSS REACTIONS; DERMATAN SULFATE; DRUG COMBINATIONS; DRUG HYPERSENSITIVITY; FACTOR XA; HEMODILUTION; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HEPARITIN SULFATE; HIRUDIN THERAPY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PERFUSION; PIPECOLIC ACIDS; PLATELET AGGREGATION INHIBITORS; PROTAMINES; THROMBOCYTOPENIA; THROMBOPHILIA; THROMBOSIS; TYROSINE;

EID: 0034741623     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/026765910101600511     Document Type: Article

References (32)

1. The thromboplastic action of cephalin
2. A simplified method of stabilization and hemostasis for minimally invasive coronary artery bypass
3. Heparin-coated hollow-fiber oxygenator without systemic heparinization in comparison to classic bubble and membrane oxygenators
4. Superior hemodynamics in left heart bypass without systemic heparinization
5. Pro and Con of heparin-bonded circuits for cardiopulmonary bypass
6. Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations
7. Safety and efficacy of heparinbonded surfaces in cardiopulmonary bypass
8. Perfusion without systemic heparinization for rewarming in accidental hypothermia
9. Heparinless partial cardiopulmonary bypass for the repair of aortic trauma
10. A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery
11. Anaphylactoid reactions to protamine: An often lethal complication in insulin-dependant patients undergoing vascular surgery
12. Coagulation pattern during deheparinization with immobilized polycation
13. Heparin removal after cardiopulmonary bypass in a patient with adverse reaction to protamine
14. Risk and benefit of low systemic heparinization during open heart operations
15. Heparin associated thrombocytopenia: Observations on the mechanisms of platelet aggregation
16. Heparin-induced thrombocytopenia and thrombosis
17. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis
18. Cardiopulmonary bypass in humans: Bypassing unfractioned heparin
19. Low molecular weight heparins
20. Heparin induced thrombocytopenia and heart operation: Management with tedelparin
21. Heparin-induced thrombocytopenia: Studies with a new low molecular weight heparinoid. Org 10172
22. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid
23. Heparin-coated catheters and heparin-induced thrombocytopenia
24. Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: A clinical evaluation of six cases
25. Ancrod (Arvin) as an alternative to heparin anticoagulation for cardiopulmonary bypass
26. Recombinant hirudin as an anticoagulant for cardiac surgery instead of heparin: First experiences
27. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass - Assessment of whole blood ecarin clotting time
28. Recombinant hirudin as an anticoagulant during cardiac surgery
29. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high risk coronary angioplasty
30. Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GP IIb/IIIa inhibitor Tirofiban as anticoagulant
31. Argatoban as anticoagulation in cardiopulmonary bypass surgery
32. Heparin-induced thrombocytopenia in coronary bypass surgery